GlassScriptPhysician profile
Kevin Colburn
NPI 1225566862
$985.19
in general payments reported to CMS, 2019-2025
11 companies · $855 in 2025
The $855 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $130 · 2025: $855.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $985.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $640.52 | 2024-2025 | |
| Lundbeck LLC | $55.08 | 2025 | Vyepti |
| Lilly USA, LLC | $54.53 | 2025 | Kisunla, Amyvid |
| Teva Pharmaceuticals USA, INC. | $52.03 | 2025 | Austedo Xr |
| Sk Life Science, INC. | $40.53 | 2025 | |
| Pfizer INC. | $36.52 | 2025 | |
| Vanda Pharmaceuticals INC. | $33.71 | 2025 | Ponvory |
| Highridge Medical LLC | $20.60 | 2024 | Biomet Spinalpak Non-Invasive Spine Fusion Stimulator System |
| Impel Pharmaceuticals LLC | $17.71 | 2025 | Trudhesa |
| Azurity Pharmaceuticals, INC. | $17.02 | 2025 | Horizant |
| Argenx US, INC. | $16.94 | 2025 | Vyvgart Hytrulo, Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Colburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.